title: [Guideline for the treatment of leprosy by new quinolones].
abstract: Ofloxacin(OFLX) is often applied today as a substitution drug of MDT for drug resistance to dapsone, rifampicin or clofazimine. However, OFLX resistance is also becoming a great concern. Low and/or irregular administration are considered to be the major causes of OFLX resistance. OFLX should be used as a combined therapy, and minimal daily dose of 400 mg of OFLX or 200-300 mg of levofloxacin is required. Quinolone resistance should be considered when no improvement of clinical and/or bacterial index is observed after the treatment for 6 months. In such cases, resistance gene detection is necessary.
authors.affiliation: Leprosy Research Center, National Institute Infectious Diseases, 4-2-1, Aoba-cho, Higashimurayama-shi, Tokyo 189-0002, Japan. m-gidoh@nih.go.jp
authors.forename: Masaichi
authors.initials: M
authors.lastname: Gidoh
authors.forename: Masako
authors.initials: M
authors.lastname: Namisato
authors.forename: Kimiko
authors.initials: K
authors.lastname: Kumano
authors.forename: Masamichi
authors.initials: M
authors.lastname: Goto
authors.forename: Reiko
authors.initials: R
authors.lastname: Nogami
authors.forename: Motoaki
authors.initials: M
authors.lastname: Ozaki
mesh_terms: D000890:Anti-Infective Agents / Q000008:administration & dosage*; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage*; D007918:Leprosy / Q000188:drug therapy*; D064704:Levofloxacin; D015242:Ofloxacin / Q000008:administration & dosage*
chemical_list: D000890:Anti-Infective Agents; D007917:Leprostatic Agents; D064704:Levofloxacin; D015242:Ofloxacin